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Abstract
Background: Establishing a large rodent model of brain metastasis that can be monitored using clinically
relevant magnetic resonance imaging (MRI) techniques is challenging. Non-invasive imaging of brain
metastasis in mice usually requires high field strength MR units and long imaging acquisition times. Using
the brain seeking MDA-MB-231BR transfected with luciferase gene, a metastatic breast cancer brain tumor
model was investigated in the nude rat. Serial MRI and bioluminescence imaging (BLI) was performed and
findings were correlated with histology. Results demonstrated the utility of multimodality imaging in
identifying unexpected sights of metastasis and monitoring the progression of disease in the nude rat.
Methods: Brain seeking breast cancer cells MDA-MB-231BR transfected with firefly luciferase (231BRL)
were labeled with ferumoxides-protamine sulfate (FEPro) and 1-3 × 106 cells were intracardiac (IC)
injected. MRI and BLI were performed up to 4 weeks to monitor the early breast cancer cell infiltration
into the brain and formation of metastases. Rats were euthanized at different time points and the imaging
findings were correlated with histological analysis to validate the presence of metastases in tissues.
Results: Early metastasis of the FEPro labeled 231BRL were demonstrated onT2*-weighted MRI and BLI
within 1 week post IC injection of cells. Micro-metastatic tumors were detected in the brain on T2-
weighted MRI as early as 2 weeks post-injection in greater than 85% of rats. Unexpected skeletal
metastases from the 231BRL cells were demonstrated and validated by multimodal imaging. Brain
metastases were clearly visible on T2 weighted MRI by 3-4 weeks post infusion of 231BRL cells, however
BLI did not demonstrate photon flux activity originating from the brain in all animals due to scattering of
the photons from tumors.
Conclusion:  A model of metastatic breast cancer in the nude rat was successfully developed and
evaluated using multimodal imaging including MRI and BLI providing the ability to study the temporal and
spatial distribution of metastases in the brain and skeleton.
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Background
The most common tumors in the central nervous system
are metastasis originating from lung and breast cancer
[1,2]. Brain metastasis occurs in 51% of breast cancer
patients, with a median survival of 13 months despite the
institution of early treatment [1,3,4]. Magnetic resonance
imaging (MRI) is a sensitive diagnostic tool with high spa-
tial resolution and excellent tissue contrast used to detect
brain metastases in patients with breast cancer [5,6] how-
ever, MRI alone cannot identify micro-metastases or track
dormant malignant cells in the brain [4,7,8]. Yoneda et al
derived the MDA-MB-231BR cell line (231BR) that is
estrogen independent from metastatic ductal carcinoma
[9,10] and specifically homes to brain [11]. Intracardiac
(IC) injection of the 231BR cells in nude mice was
reported to form metastases in the brain and therefore
animal models based on this cell line have been used for
this purpose [8,12,13]. Recently, the 231BR was trans-
fected with enhanced green fluorescent protein (EGFP)
and following IC injection in mice and metastases were
detected brains by optical imaging and fluorescent micro-
scopy [14]. Heyn et al labeled 231BR-EGFP cells with flu-
orescent micron-sized superparamagnetic iron oxide
(MPIO) particles, and injected these cells into nude mice
[15].
Single MPIO labeled breast cancer cells appeared initially
after IC injection in the mouse as dark or hypointense
voxels in the brain parenchyma on T2* weighted MRI that
subsequently developed into metastases over 4 weeks
[15]. Heyn et al reported that between 1-3% of the ini-
tially injected MPIO labeled cells remained in the brain to
form the visible tumors on MRI [15]. Some of the labeled
231BR-EGFP cells were considered "dormant" based on
the persistence of the hypointense signal in the same loca-
tion of the brain over 28 days. Fluorescent microscopy
demonstrated the presence of 231BR-EGFP cancer cells
located within the cerebral vasculature in approximately
the same location as the hypointense voxels on MRI.
However, imaging studies with the brain seeking 231BR-
EGFP breast cancer cell line have only been performed of
the brain and therefore possible metastases in other tis-
sues were not observed [15].
The goal of this study was to develop a rat model of brain
metastases using the brain seeking breast cancer cell line
231BR that could be monitored with a clinical 3 tesla
MRI. The 231BR cells were used because several reports
have indicated that this breast cancer cell line was brain
seeking and metastases were observed only in the brain by
non-invasive imaging and histology [11-13,15]. The
231BR cells were stably transfected with firefly luciferase
(231BRL) in order to determine the distribution of the
breast cancer metastasis over time by bioluminescent
imaging (BLI). The 231BRL cells were magnetically
labeled with ferumoxides complexed with protamine sul-
fate [12-21] in order to monitor the early implantation of
tumor cells in the brain and to determine the sensitivity of
T2* weighted 3 tesla MRI to the labeled cells and the sub-
sequent detection of multiple metastases. Most MR imag-
ing studies of brain metastases have been performed in
mice using high field strengths scanners (i.e., ≥ 7 tesla)
because of the ability to obtain high spatial resolution and
signal to noise as compared to images obtain using a clin-
ical scanners [22,23]. Moreover, we employed multimo-
dality imaging to direct the pathological examination
from the unexpected areas of breast metastases that
occurred following the IC infusion of the brain seeking
231BR breast cancer cell line [11].
Methods
Tumor cell line
The 231BR breast cancer cell line [11] was transfected with
the mammalian expression vector pGL3-control
(Promega Corporation, Madison, WI) using effectene rea-
gent (Qiagen, Germantown, MD) according to the manu-
facturer's protocol to tag the cells with the firefly luciferase
gene for bioluminescent imaging. The cells were co-trans-
fected with pcDNA3.1 containing a neomycin resistance
gene for the selection of clonal populations of luciferase
expressing cells. Forty-eight hours after transfection cells
were incubated in growth media containing 800 μg/ml
G418 (Invitrogen, Carlsbad, CA) and single clones
selected after 4 weeks in culture. Luciferase expression was
confirmed using the Steady-Glo Luciferase Assay System
according to the manufacturer's protocol (Promega Cor-
poration, Madison, WI). The clone with the highest
expression was used in the experiments described herein
for the BLI tumor detection system. The cell line was cul-
tured with DMEM growth media containing 10% fetal
bovine serum and 1% penicillin streptomycin antibiotics
(Invitrogen, Carlsbad, CA) at 37°C in room air with 5%
CO2.
Ferumoxides-Protamine Sulfate (FEPro) labeling of 
231BRL cells
The 231BRL cells were labeled with the commercially
available ferumoxides (Feridex IV®, 11.2 mg/ml, Bayer-
Schering Pharmaceutical Inc, Wayne, NJ) contrast agent
complexed to preservative free protamine sulfate (10 mg/
ml, American Pharmaceuticals Partner, Schaumburg, IL)
as previously described [13]. 231BRL cells were cultured
until they reached 90% confluence. Ferumoxides (FE) and
protamine sulfate (Pro) were mixed in fresh serum free
RPMI 1640 medium (Biosource, Camarillo, Ca) at con-
centration ratio of FE:Pro of 100 μg/ml:6 μg/ml of media.
The cells were incubated for two hours followed by over-
night incubation with complete media. Labeled cells were
washed 3 times with 10 unit/ml of heparinized PBS and
trypsinized. Determination of average iron concentrationJournal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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per cell was done using a variable-field relaxometer
(Southwest Research Institute, San Antonio, TX) as previ-
ously described [12,16,24].
Cellular viability and proliferation
A trypan blue exclusion test was performed to determine
the effect of FEPro labeling on the 231BRL cell viability.
To determine the proliferation capacity of the FEPro
labeled cells, MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-car-
boxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium,
inner salt) cell proliferation assay (CellTiter 96® AQueous
One Solution, Promega, Madison, WI) was performed
using the manufacturer's protocol.
All in vitro measurements were performed in triplicate.
Animal model
This study was conducted under an approved Animal Care
and Use Committee (ACUC) protocol at our institution.
All procedures were performed using sterile technique. In
vivo imaging studies including IC injection, BLI and MRI
were performed with isoflurane gas anesthesia 2-3%
mixed with 100% O2 by nosecone and body temperature
was maintained 37°C. FEPro labeled or unlabeled
231BRL cells were suspended in 10 units/ml heparin in
phosphate buffered saline (PBS). Tumor cells were intro-
duced into the left ventricle under ultrasound guidance
using a 14 MHz linear probe (Acuson Sequoia C256, Sie-
mens Medical Solutions, Malvern, PA). Thirty-one female
nude rats (NIH-rnu from Charles River, Wilmington, MA)
at 6 to 8 weeks of age were divided into 3 groups for this
study. Table 1 is a summary of the experimental design.
Two cell doses were used in order to establish the minimal
numbers of cells that would be required to establish this
metastatic model in the nude rat. Group 1 consisted of 18
rats that received 3 × 106 FEPro labeled 231BRL cells by IC
injection. Serial MRI and BLI studies were performed as
part of a study and cohorts of animals were euthanized at
specific time points (day 1,3 and weeks 1,2,3) post IC
injection to determine the distribution of metastases in
the brains at specific points in time. Group 2 rats (n = 8)
were injected with 106 FEPro labeled 231BRL cells and
were evaluated for the distribution of metastasis with con-
firmation on histological examination. Group 3 (n = 5)
rats were injected 106 unlabeled 231BRL cells and served
as controls for the imaging studies.
Imaging procedures
MRI scanning was performed on a clinical 3 tesla MRI unit
(Intera, Philips Medical System, Netherlands, B.V.) with
using a solenoid 4 cm radiofrequency receive only coil
(Philips Research Laboratories, Germany) for rat brain.
Physiological monitoring was performed with SAII MRI
compatible unit (Small Animal Instruments Inc., Stony
Brook, NY). The MR pulse sequences were as follows: T2-
weighted (T2w) turbo spin echo (TSE) sequence, repeti-
tion time (TR)/echo time (TE) = 3200/60 ms, turbo spin
echo factor 12, number of average (NAV) 8, field of view
(FOV) 50 mm, slice thickness 0.5 mm, matrix 224 × 256,
reconstructed resolution 100 × 100 μm, slice number 25;
and a T2* multi echo gradient sequence (T2*w), TR/effec-
tive TE = 4560/28 ms, 15 echos, flip angle 30°, NAV 2,
FOV 50 mm, slice thickness 0.5 mm, matrix 176 × 256,
reconstructed resolution 200 × 200 μm. For contrast
enhanced MRI studies gadopentetate dimeglumine
(GdDTPA, 0.5 M, Magnevist, Bayer Schering Pharmaceuti-
cals, NJ) at a dose of 0.3 ml/kg was injected through lat-
eral tail-vein. Pre and post GdDTPA enhanced 3D T1-
weighted (T1w) fast field echo (FFE) sequence were per-
formed with TR/TE = 35/4 ms, flip angle 35°, NAV 8, FOV
50 mm slice thickness 0.5 mm × 25 sections and matrix
224 × 256 with a reconstructed in plane resolution 100 ×
100 μm. The total MRI scanning time was less than 50
minutes per rat. For Group 2 and 3 rats, hyperintense
masses on T2 weighted images on pre-euthanasia scans
were manually counted and matched to regions of the
brain in order to determine the distribution of metastases.
MRI studies were also performed in Group 2 and 3 rats to
validate the presence of photon flux activity detected on
BLI along the spinal cord of the animals. Sagittal MRI was
performed of the spine as follows: T2w with TSE 3200/60
msec, field of view 50 mm, 0.5 mm slice thickness, matrix
224 × 172 reconstructed to 100 × 100 μm in plane resolu-
Table 1: Experimental Design
Days Group A rats (n = 18) Group B rats (n = 8) Group C rats (n = 5)
Prior to infusion of cells MRI baseline MRI Baseline MRI Baseline
Day 0 IC injection 3 × 106 FEPro labeled 231BRL 106 FEPro labeled 231BRL 106 unlabeled 231BRL
Day 1 MRI and BLI Euthanized 4 of 18 rats MRI and BLI MRI and BLI
Day 2 -- MRI and BLI MRI and BLI
Day 3 MRI and BLI Euthanized 4 of 14 rats MRI and BLI MRI and BLI
Week 1 MRI and BLI Euthanized 5 of 10 rats MRI and BLI MRI and BLI
Week 2 MRI and BLI Euthanized 3 of 5 rats MRI and BLI MRI and BLI
Week 3 MRI and BLI Euthanized all rats MRI and BLI MRI and BLI
Week 4 - Euthanize 8 rats - - Euthanize 5 rats -Journal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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tion and T1w contrast enhanced FFE with 35.4/4.2 msec
and flip angle of 35° with a field of view 50 mm and 0.5
mm slice thickness matrix size 224 × 172 reconstructed to
100 × 100 μm in plane resolution.
Bioluminescence imaging was performed using IVIS™ 100
system and analyzed with Living Image® software (Xeno-
gen, Alameda, CA). For in vitro studies, FEPro labeled and
unlabeled 231BRL cells were prepared in a black 96 well
plates (Corning Costar Company, Cambridge, MA) from
105 cells to 195 cells per well and D-luciferin Firefly (syn-
thetic sodium salt monohydrate, Biosynth International,
Inc, Naperville, IL) was added to each well at a concentra-
tion of 150 μg/ml. Total photon flux from each well was
obtained over 1 minute and correlated to the numbers of
cells per well. The in vivo BLI was performed following
intraperitoneal injection of luciferin substrate at concen-
tration of 150 mg/kg at 10-15 minutes following injection
with a 3-minute acquisition time. The BLI photon flux in
photons/sec/cm2/steradian was obtained and compari-
sons were made to the serially acquired images. The back-
ground photon flux was measured at the outside of the rat
and was automatically subtracted.
Histopathology
The rats were euthanized with an overdose of pentobarti-
tal Sodium (Nembutal, 50 mg/ml, Ovation Pharmaceuti-
cals Inc., Deerfield, IL) and were perfused with heparinzed
saline and 4% paraformaldehyde for histological exami-
nation. Brain, spinal cord, lung, liver, spleen, kidney,
lymph node, bone marrow, and tumors in decalcified
long bone and spine were harvested from animals. Six-
micron thick sections were obtained and stained with
hematoxylin and eosin of brain and other organs that had
photon flux activity on pre-terminal BLI. Histological sec-
tions were of the brain were obtained in approximately
the same plane as MRI to allow for imaging pathological
comparisons. Consecutive sections were obtained for
immunohistochemistry. IgG anti-human cytokeratin anti-
body (AE1/AE3, DacoCytomation, Denmark) and mouse
IgG Vectastain®  Elite ABC Kit was used to detect the
human breast cancer cells. Immunostaining kits were pur-
chased from Vector laboratories (Vector Laboratories,
Inc., Burlingame, CA). Sections were incubated with bioti-
nylated secondary antibody for 30 min and enhanced
with 3,3'-diaminobenzidine (DAB). Counterstaining was
done with Vector® Hematoxylin QS. Consecutive sections
were stained with Perl's reagent (Prussian blue) for the
presence of iron and counterstained with nuclear fast red
as previously described [17,24,25]. Approximately 5-10
consecutive histological sections of the brain and selected
tissues were analyzed and photographed under light
microscopy (BX50F, Olympus Optical Co., LTD., Japan)
for each rat. The images were processed using Adobe Pho-
toshop 7.0 (San Jose, CA).
Statistical analysis
In vitro study results were entered into standard spread-
sheet software package and statistical significance was per-
formed using two-tailed t test with P < 0.05. A regression
analysis was performed to correlate cell number to the
photon flux. All results are reported as the mean ± stand-
ard deviation.
Results
Cell labeling and in vitro analysis
Prussian blue (PB) staining proved homogenous high effi-
cient labelling of 231BRL cells with FEPro (Additional file
1A). There were no significant differences between FEPro
labeled and unlabeled cells in Trypan blue viability (i.e.,
97.9% ± 1.96 versus 98.8% ± 1.98,) or for proliferation
capacity as measured by MTS assay (i.e., Absorbance
1.244 ± 0.13 versus 1.158 ± 0.23). The average (n = 3 sam-
ples) intracellular iron content of was 10.7 ± 1.9 pg/cell
for FEPro labeled cells and 0.3 ± 0.03 pg/cell for unlabeled
231BRL cells. There was a correlation between the cell
number and photon flux intensity in vitro (Additional file
1B). Bioluminescence photon flux intensity of the
231BRL cells was not affected by FEPro labeling over the
range of cell numbers evaluated with a minimum detec-
tion limit of 195 cells (Additional file 1C).
In vivo imaging with histological correlation
MRI scans from group 1 rats that were euthanized at dif-
ferent time points is shown in Figure 1. T2*w images in
the coronal plane demonstrate numerous hypointense
(i.e., dark) voxels distributed throughout gray and white
matter of 231BRL cells on days 1 and 3 post IC injection.
The hypointense voxels were not observed on baseline
scans in rats prior to receiving FEPro labeled cells (data
not shown). Hypointense voxels were not detected on
T2w images.
Pathological examination of rats euthanized on day 1-3
post cell infusion showed evidence of single or clusters of
breast cancer cells in capillaries throughout the brain that
were PB and cytokeratin positive (Figure 1). The location
of PB positive cells in histology were in the approximate
location as the hypointense voxels on T2*w MR imaging
(Figure 2). One to two weeks post infusion of FEPro
labeled cells brain sections were negative by Prussian blue
stain in 50% of the Group 1 rats. By week 2 post-injection
of labeled 231BRL cells, small (i.e., 200-300 μm) hyperin-
tense (i.e., bright) regions newly observed in the brain on
T2w images consistent with new tumor formation and not
infarction since these lesions were not observed on previ-
ous T2 weighted images. Histological examinations of the
brain sections from rats euthanized week 2 post IC injec-
tion revealed metastases ≥ 200 μm in size and no evidence
of hemorrhage or infarction within the brain was
observed. The differences in the slice thickness betweenJournal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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the histological section (6 μm) and MRI (500 μm) pre-
cluded the direct spatial co-localization of FEPro contain-
ing cells to the hypointense voxels on the T2*w image, the
distribution of breast cancer cells appeared in similar
areas of gray and white matter based on anatomical land-
marks from MRI and histological sections. In order to
reduce the Gibbs (ringing) image reconstruction trunca-
tion artefact [26] observed on the coronal plane T2w and
T2* w images in the group 1 rats, MRI studies performed
in the Group 2 and 3 rats were acquired in the oblique
axial plane.
Figure 3 contains examples of serial BLI and oblique axial
MRI scans from one of the group 2 and group 3 rats. Serial
BLI revealed intense photon flux activity originating from
the brain within the first 2 days after injection of 231BRL
cancer cells in group 2 and 3 rats (Figure 3). T2*w images
performed on day 2 post FEPro labeled 231BRL cell injec-
tion shows numerous hypointense voxels distributed in
the cerebrum, brain stem and upper cervical regions in
Group 2 rats. Hypointense voxels were not detected on
T2*w images from Group 3 at any point following infu-
sion of cells. Region of interest from the head of group 2
In vivo cellular MRI with histological validation of brain metastases in group 1 rats Figure 1
In vivo cellular MRI with histological validation of brain metastases in group 1 rats. Representative group 1 rats 
that received 3 × 106 FEPro labeled 231BRL cells with each column matched to the same animal. T2*-weighted images demon-
strate diffuse brain metastasis of tumor cells as hypointense voxels on days 1 and 3 post intracardiac injection. Arrowheads 
mark some of the hypointense regions. Growing metastatic breast cancers were greater than 200-300 μm in size at week 2. 
T2-weighted image shows hyperintense tumor at left hippocampus at week 2 (arrowhead). Cytokeratin immunohistochemical 
staining (CK IHCS) of the brain showed tumor cells (i.e., brown) in the microvasculature of the brain at the early period (day 
1-3, arrow) and growing mass at the later time points (week 1-2). Prussian blue iron staining were compatible findings to CK 
IHCS staining for tumor cells. Bar: MRI = 4 mm, histology = 200 μm.Journal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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and 3 rats revealed an increase in photon flux activity on
Day 2 that rapidly decreases by Day 3 through week 1 post
IC injection of breast cancer cells. This rapid decrease in
photon flux between day 3 through week 1 to near back-
ground is consistent with the decrease in number of
hypointense voxels on T2*w images and clearing of FEPro
labeled 231BRL cells from brain. This change in signal
intensity on MRI occurring days after infusion of FEPro
labeled cells indicates that either cell metabolized or
diluted ferumoxides through multiple cell divisions or
only minority of the breast cancer cells remained in the
brain, marginated into the parenchyma, proliferated and
formed metastases. The disappearance of hypointense
voxels during this period of time occurred in 100% of
Group 2 rats. Between weeks 1 and 3 post infusion of
FEPro labeled cells, there was limited evidence of tumor
cell proliferation detected by BLI (Figure 3). Photon flux
decreased from 5.91 × 106 photon/sec to 1.03 × 105 pho-
ton/sec levels between day 2 and week 1 post infusion of
cells with a rapid rise in bioluminescent activity at 3 weeks
to above day 1 levels (> 107 photons/sec) and was consist-
ent with tumors detected by MRI and on histological
examination (Additional file 2).
T2w images between 2-4 weeks post IC injection of
231BRL revealed multiple metastases in the brain. The
distribution of brain metastases in groups 2 and 3 rats by
week 3-4 was similar to that observed in the group 1 ani-
mals on the imaging studies. The majority of hyperintense
brain metastases on T2w were located in the cerebral cor-
tex (100%), thalamus and hypothalamic regions (92%),
hippocampus and pons/medulla (85%) and tumors were
less commonly found (> 55%) in the olfactory bulb, cere-
bellum and midbrain regions.
Histological findings in metastases in the body
The distribution of breast cancer metastases determined
from histology and imaging for the three cohorts of ani-
mals was summarized on Table 2. Labeling the 231BRL
cells with FEPro did not alter the breast cancer cells ability
to produce metastases in the brain. The development of
metastatic breast cancer was organ dependant. Figure 4
contains representative BLI and MRI of the distribution of
metastases in the spinal cord and bones. Prussian blue
MRI with histological correlation of group 1 rat Figure 2
MRI with histological correlation of group 1 rat. Prus-
sian blue staining of the coronal section of brain and MRI 
shows the distribution of ferumoxides labeled cells in the 
brain at day 1 post IC infusion of 3 × 106 cells. The T2*w 
image shows many hypointense spot due to metastatic tumor 
cells in the cerebral cortex and hippocampus. Inset in the 
MRI indicates the area photographed in Prussian blue staining 
(center). Although the differences in the slice thickness of the 
histological section (6 μm) and MRI (500 μm) precluded 
direct spatial co-localization of iron positive lesions, the dis-
tribution pattern of metastasis can be appreciated.
Bioluminescence imaging and MRI obtained from representa- tive a rat from Group 2 and Group 3 Figure 3
Bioluminescence imaging and MRI obtained from 
representative a rat from Group 2 and Group 3. First 
column contains representative images from Group 3 rats 
that received unlabeled breast cancer cells. Columns 2-6 (left 
to right) contain serial scans from Group 2 rat that received 
106 FEPro labeled 231BRL cells. At day 2, BLI demonstrate 
intense photon flux from the brain from both groups of ani-
mals. T2*-weighted images demonstrate the presence of 
numerous hypointense voxels containing labeled cells (mid-
dle row, arrowhead). Arrows on T2-weighted images indi-
cates growing metastatic breast cancer that can be seen as 
early as 2 weeks after infusion of cells.Journal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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staining was usually negative for iron one week after infu-
sion of FEPro labeled cells, however isolated PB positive
breast cancer cells could be detected in the brain paren-
chyma at euthanasia in 5 of 8 of the group 2 rats (Figure
4E). All rats presented metastatic breast cancer cells in the
bone marrow and multiple lytic bone lesions in axial and
appendicular skeleton as early as week 2. Both spinal cord
and vertebral body metastases were observed in this
model along with tumor cell infiltrations in and around
joint spaces (Figure 4J).
All rats had evidence of tumor cell infiltration in the
lymph nodes with distortion of nodal architecture. Lung,
liver and renal metastases were found in animals eutha-
nized at later time points however mass lesions (> 200
μm) were rarely seen (Additional file 3). In the spleen,
breast cancer cells were diffusely disseminated throughout
red and white pulp but no discrete mass lesions were
found.
Discussion
The development of a relevant large rodent model of
brain metastases that can be monitor using relevant non-
invasive techniques is needed to investigate the early dis-
tribution pattern of tumors and translate the imaging
approaches to the clinic [8]. The major finding of this
study was the documentation using multimodality imag-
ing approach of the development of tumor metastases
model in the nude rat using the brain seeking 231BRL cell
line. Bioluminescent imaging and MRI demonstrated pri-
marily brain and bone metastases from this brain seeking
breast cancer cell line. The 231BR breast cancer cell line
was chosen for this study since it reported only produced
brain metastases [11-13,15] and we wanted to determine
if we could develop model in large rodent and possibly go
on to use bioluminescent activity in the brain as an out-
come measure for future treatment. The surprising finding
was that all of the breast cancer 231BR cell lines resulted
in bone metastasis that was not previously described and
missed on pathological examination. The results of this
study strongly indicate the need of noninvasive whole
body imaging when developing a new animal model.
Jenkins et al [27] reported that following the transfection
of MDA-MB-231 cells with firefly luciferase, the pattern of
Central Nervous System and skeletal involvement by breast  cancer Figure 4
Central Nervous System and skeletal involvement by 
breast cancer. A) Bioluminescence image of rat at week 3 
shows high photon flux activity from the brain, spine, and 
joints. (B) Sagittal T2w MRI and (C) contrast enhanced T1w 
MRI show hyperintense lesions on the brain, spinal cord, and 
vertebral bodies (arrowheads). Histological section of brain 
(D) and spinal cord (F) with hematoxylin and eosin (HE) 
staining from group 2 rat euthanized at week 4 reveals 
numerous metastases (arrowheads). E) Prussian blue staining 
of the consecutive brain section from D shows few isolated 
iron positive cells near the tumor (arrows). H) Thoracic 
spine with tumor infiltration on HE stain. Cytokeratin 
immuno-histochemical staining of the bone marrow aspirates 
(G) and Spine (I) is positive for tumor. J) Knee joint metasta-
sis with extraskeletal involvement is seen (arrowheads) on 
HE stain.
Table 2: Distribution of metastatic tumor determined on histology and imaging
Group 1 Group 2 Group 3
% Day 1 (n = 4) Day 3 (n = 4) Week 1 (n = 5) Week 2 (n = 3) Week 3 (n = 1) (n = 8) (n = 5)
Braina 0 0 80 100 100 87.5 80
Spinal Corda 0 0 80 100 100 87.5 80
Lunga 0 0 02 00 5 0 6 0
Livera 0 0 20 33.3 100 0 0
Kidneya 0 0 60 100 100 87.5 60
Lymph Nodea 0 0 100 100 100 100 100
H e a r t 0 0 000 0 0
Boneb 100 100 100 100 100 100 80
Note. a. Tumor cells within the vasculature or tissue on day 1 and 3 were not counted.
b. Positive tumor cells detected by immunohistochemical staining of bone marrow sample were considered as positive lesion on group 1 rats. 
Group 2 rats underwent histological examination of long bone and spine for bone tumor determination. In group 3 rats, bone tumor lesions were 
determined on MRI and BLI.Journal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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metastases was altered compared to the parent cell line
and resulted in tumors in bone, brain, liver, lungs, lymph
nodes, and kidneys. In this study, the fluc gene transfected
231BR cells also caused bone metastases in a similar dis-
tribution as previously reported in mice [27]. In addition,
the distribution of brain metastases in the rat model was
similar to previous report in mice injected with green flu-
orescent protein transfected 231BR cell line [12]. Of note,
we have IC infused 231BR or 231BRL cells into nude mice
and have observed development of bone metastases on
BLI and micro CT scan (Additional file 4). These results
indicate that the introduction of fluc into the cell genome
appears to have altered the propensity of selective metas-
tases of the 231BR cells to just the brain. Differences in
genotype expression of the 231BRL cells at the various
metastatic sites would be impressive but highly unlikely
or significant and would require gene chip analysis that is
beyond scope of this work. The findings in this study sup-
port the importance of multimodal imaging in the devel-
opment and evaluation of cell lines intended to model
clinical disease or home to a specific target tissue.
In the current study, photon flux activity was not visible
originating from the brain in 75% of the Group 1 rats
between weeks 1 to 2 post IC injection of cells, even
though metastases were detected over 80% of rats on his-
tology and MRI. The region of interest analysis of the pho-
ton flux from the heads of the group 2 rats between day 3
and week 1 shows an abrupt decrease toward background
level (Additional file 2). The decrease in photon flux
intensity in the rat brain between day 3 and week 1 post
IC injection may be attributed to a change in pigmenta-
tion of the hair and skin of the animals [28], tumor cells
being cleared from brain vasculature, areas of tumor
hypoxia or poor delivery of luciferin to the tumors.
Although the measured photon flux intensity from the
brain region at week 3 is elevated compared to day 1 post
infusion of 231BRL cells (Additional file 2), brain metas-
tases detected on T2w images were not always present on
BLI (Figure 3). Extrapolation from the in vitro photon flux
activity versus numbers of the 231BRL cells injected
(Additional file 1) would estimate that approximately
8.5% of the initially IC injected 106 tumor cells were
located in the head on day 2. Between day 3 and week 1,
the photon flux decreased and was estimated to be
approximately 0.6% of the cells that remained or survived
in the rat brain ultimately going on to form metastases.
Heyn et al [15], reported that between 1-3% of the ini-
tially injected MPIO labeled cells remained in the mouse
brain and went on to form the metastases at 4 weeks post
infusion of cells. The difference between these two studies
probably can be contributed to the size of the animals, the
fluorescent versus luminescent labels in breast cancer cells
and the in vivo optical imaging devices used and that
MPIO are not metabolized in cells as compared to feru-
moxides that dissolves in endosomes [29,30]
The disappearance of hypointense voxels (i.e., voxels
becoming isointense to surrounding brain) on the T2*w
images by week 1 post IC injection of cells can be due to
multiple factors including dilution of the FEPro label in
rapidly proliferating cells [17], iron metabolism [29,31]
and/or the cells became apoptotic or died and were
cleared from the vasculature before marginating into the
parenchyma. Prussian blue stain of the brain revealed rare
cells with intracellular iron in the cortex of 50% and
62.5% of group 1 and 2 rats euthanized at 2-4 weeks,
respectively. The small numbers of PB positive cells were
not detected using T2* weighted images probably because
of the spatial resolution and image contrast (Figure 4E).
The finding of isolated PB positive cells on histology
would suggest the need for quantitative imaging
approaches such as T2* maps that can be possibly corre-
lated to amount of iron present in the brain [32,33]. Heyn
et al [34] reported the detection of a single MPIO labeled
breast cancer cells in the brains of mice with a modified
clinical 1.5T MR scanner using acquired with a voxel size
of 39 × 39 × 100 μm at 4 weeks post infusion of cells. The
apparent difference in being able to detect single dormant
breast cancer cells at > 1 week post infusion between the
latter study and current study (voxel size 100 × 100 × 500
μm) maybe due to the increased susceptibility effect gen-
erated by the MPIO versus the SPIO nanoparticles, smaller
voxel size produced by MRI hardware modification and
the MPIOs are not metabolized by the cell. The combina-
tion of quantitative T2* MR imaging performed prior to
and post infusion of magnetically labeled cell should pro-
vide investigators with the ability to detect subtle changes
in T2* maps that would indicate the persistence of SPIO
in cells in the brain [35] that may be used in cell therapy
trials.
MRI and BLI provided serial non-invasive assessment of
the formation of metastases over time in the same cohort
of animals. In the current model, 84.6% of all the animals
developed brain metastases in 4 weeks when 106 cells
were administered in 6 week-old nude rats. The distribu-
tion of 231BRL metastases in the rat brain on MRI is sim-
ilar that has recently been observed on histological
examination of the mouse brain following IC injection of
the 231BR-EGFP by Fitzgerald et al [12]. In the current
study, metastases in the olfactory bulb and cerebellum
were not as common as observed in the mouse brain [12].
This difference may be contributed to MRI inability to
clearly delineate micro-metastases because of image con-
trast on T2w images. The intent of this study was to
develop a model of breast cancer metastases in the rat
brain using a cell line that had been shown to produceJournal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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brain metastases that could be detected using a clinical 3
tesla MRI unit. BLI demonstrated that IC injection of this
brain seeking fluc transfected 231BR breast cancer cell line
resulted in the development of metastases in the skeleton.
Follow-up high-resolution MRI studies of these areas con-
firmed the presence of metastatic breast cancer. By using
this multimodality approach, spinal cord metastases were
also detected by MRI (Figure 4B-C) that had previously
not been identified in mouse model studies using the
231BR cell line [11,14,15]. Of note, spinal cord metastasis
represents about 8.5% of CNS metastasis and affects 0.1
to 0.4% of cancer patients [36]. The detection of spinal
cord metastases by MRI underscores the importance on
using multimodality imaging techniques to evaluate
experimental models of metastatic disease.
Conclusion
In this study, serial BLI and MRI were used to track the
temporal and spatial distribution of breast cancer from
the 231BRL cell line and the formation of metastases in
the rat brain. MRI detected brain metastases in the rat
brain 2-4 weeks following the IC injection of 106 231BRL
cells in this highly reproducible model and findings con-
firmed on histological examination. Multimodality imag-
ing detected the presence of metastases in the brain and
spinal cord, bone and other internal organs during the
disease course demonstrating the important role of in
vivo imaging in the development of an experimental
model. This rat model and non-invasive clinically relevant
MRI techniques and BLI should be useful for the develop-
ment of novel targeted drug, cellular and molecular ther-
apies for the treatment of metastatic breast cancer.
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Additional material
Additional file 1
Validation of FEPro labeling and bioluminescence photon flux inten-
sity. A) Prussian blue staining (blue color) of the FEPro labeled human 
breast cancer cells proved homogenous intracellular labeling of the cells. 
Inset shows unlabeled control cells. B) The number of MDA-MB-231BRL 
breast cancer cell and bioluminescent signal intensity was linearly corre-
lated (R2 = 0.9997). Bioluminescence activity was measured as total pho-
ton flux for each well. C) Well plate measurement of bioluminescent 
intensity of FEPro labeled and unlabeled 231BRL cells show no difference. 
D) Table shows actual photon count from well experiment of (C). E) 
Average photon count of 4 session of triplicate experiment. No statistical 
significance of difference of photon count before and after FEPro labeling 
was proved.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-7-88-S1.TIFF]
Additional file 2
Region of interest photon flux analysis from the brain and whole body 
in group 2 rats. BLI on Day 2 shows a peak in the photon flux activity 
originating from the brain whereas activity from the body was at its min-
imum from days 2-3 post infusion of the 231BRL cells. Photon flux from 
the body increases rapidly in the body from weeks 1-3 and has greater 
number of counts as compared to the brain. Whole body does not include 
photon flux from brain.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-7-88-S2.TIFF]
Additional file 3
Organ involvement of the metastatic tumor. Hematoxylin and Eosin 
(HE) and cytokeratin (CK) staining of the major internal organs are 
shown. Diffuse breast cancer cell infiltrations were present in the lym-
phoid tissue of the lung, lymph nodes and spleen. Hepatic periportal tumor 
cell infiltration in the liver (double arrow in CK in Liver) was frequently 
observed in the rats. Hepatic sub-capsular metastatic lesions were rarely 
found (arrow). Tumor cell infiltrations in renal glomeruli were also fre-
quently observed (arrows).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-7-88-S3.TIFF]
Additional file 4
Bone metastases produced by brain seeking breast cancer cell in the 
nude mouse. A) An example of one of the nude mice (n = 6) that received 
1×105 brain seeking luciferase transfected MDA-MB-231BR cells report-
edly the brain seeking breast cancer cell line by intracardiac injection. 
Three weeks post injection of cells bioluminescence images show photon 
flux activity over the spine (arrows), head, scapular, lung and kidney 
(arrowheads). B) Three dimensional volume rendered image by using 
MicroCAT II micro CT scanning system (Siemens Preclinical Solutions, 
Knoxville, TN) of nude mouse at 5 week from intracardiac injection of 
1×105 MDA-MB-231BR cells. Multiple osteolytic lesions on the proximal 
shoulder, scapular, knee, and spine are seen (arrowheads).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-7-88-S4.TIFF]Journal of Translational Medicine 2009, 7:88 http://www.translational-medicine.com/content/7/1/88
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